Pacira Pharmaceuticals

88 total trials 5 currently recruiting 65 completed

Pacira Pharmaceuticals sponsors 88 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 65 completed. 38 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis of the Knee, with 4 trials.

Trial Pipeline

88 total, page 1 of 2

RECRUITING Phase 2

A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

NCT06884865
RECRUITING NA

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity

NCT06340451
RECRUITING Phase 1

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265
RECRUITING Phase 3

ZILRETTA in Subjects With Shoulder Osteoarthritis

NCT06269705
RECRUITING

Innovations in Genicular Outcomes Registry

NCT05495334
ACTIVE NOT RECRUITING Phase 1

Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

NCT04119687
TERMINATED Phase 2

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

NCT06977568
COMPLETED Phase 1

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

NCT05456490
COMPLETED Phase 3

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

NCT05157841
COMPLETED Phase 3

Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty

NCT05139030
COMPLETED Phase 1

Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy

NCT04826328
COMPLETED Phase 3

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries

NCT04518462
TERMINATED NA

Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty

NCT04191031
TERMINATED Phase 1

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers

NCT04173611
COMPLETED Phase 1

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

NCT04293809
TERMINATED Phase 2

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

NCT04160091
TERMINATED Phase 4

Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

NCT03927911
COMPLETED Phase 2

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

NCT04065074
COMPLETED Phase 1

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

NCT04002089
COMPLETED Phase 3

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03682302
COMPLETED Phase 4

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
TERMINATED Phase 3

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

NCT03793010
TERMINATED Phase 1

Study in Adult Subjects Undergoing Posterolateral Thoracotomy

NCT03428984
COMPLETED Phase 3

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

NCT03529942
COMPLETED Phase 1

Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03485014
COMPLETED Phase 2

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

NCT03382262
COMPLETED Phase 2

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
COMPLETED NA

Treatment With Iovera° for Total Knee Arthroplasty (TKA) Post-Operative Pain

NCT03327220
COMPLETED Phase 4

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

NCT03176459
TERMINATED Phase 4

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

NCT03015961
COMPLETED Phase 3

Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

NCT03046446
COMPLETED Phase 1

PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery

NCT02985762
TERMINATED Phase 2

Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA

NCT02922582
COMPLETED Phase 3

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

NCT02713178
COMPLETED Phase 3

Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery

NCT02713230
COMPLETED Phase 4

Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty

NCT02713490
COMPLETED Phase 2

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

NCT02762370
COMPLETED Phase 2

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

NCT02637323
COMPLETED Phase 3

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

NCT02517905
TERMINATED Phase 4

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
TERMINATED Phase 2

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

NCT02468583
COMPLETED Phase 3

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

NCT02357459
COMPLETED Phase 4

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty

NCT02284386
COMPLETED NA

A Randomized, Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty

NCT02284113
COMPLETED NA

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

NCT02260921
COMPLETED Phase 4

EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty

NCT02255500
COMPLETED Phase 4

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

NCT02199574
COMPLETED Phase 1

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

NCT02210247
COMPLETED Phase 2

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

NCT02116972
COMPLETED Phase 2

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

NCT02003365
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 22
Phase 3 17
Phase 4 21

Therapeutic Areas

Osteoarthritis of the Knee 4
Postoperative Pain 3
Pain Management 3
Knee Osteoarthritis 2
Pain 2
Osteoarthritis, Knee 2
Histological Response of Tissue to Cold 1
Frown Lines 1
Breast Augmentation 1
Facial Wrinkles 1

What the Pipeline for Pacira Pharmaceuticals Shows

According to the ClinicalTrials.gov registry, Pacira Pharmaceuticals is linked to 88 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting, about 6% of the sponsor's indexed portfolio, and 65 are already marked complete, representing roughly 74% of the total.

The phase mix for Pacira Pharmaceuticals reports 38 late-stage studies (Phase 3 and Phase 4 combined) and 35 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for Pacira Pharmaceuticals is Osteoarthritis of the Knee with 4 linked trials, and 9 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.